Last reviewed · How we verify
Trelstar (triptorelin)
Trelstar works by binding to and activating the gonadotropin-releasing hormone receptor, which leads to a decrease in testosterone production.
At a glance
| Generic name | triptorelin |
|---|---|
| Sponsor | Verity |
| Drug class | Gonadotropin Releasing Hormone Receptor Agonist |
| Target | Gonadotropin-releasing hormone receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2000 |
Mechanism of action
Think of it like a key fitting into a lock. Trelstar is the key that fits into the gonadotropin-releasing hormone receptor lock, which then sends a signal to the body to reduce testosterone production. This helps to slow the growth of prostate cancer cells that rely on testosterone for growth.
Approved indications
- Advanced Prostatic Carcinoma
Common side effects
- Ovarian hyperstimulation syndrome
- Needle issue
- Syringe issue
- Disease progression
- Prostatic specific antigen increased
- Product prescribing issue
- Product use complaint
- Ascites
- Osteonecrosis of jaw
- Product reconstitution quality issue
- Product administration error
- Incorrect dose administered
Key clinical trials
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2,PHASE3)
- Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (PHASE3)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2,PHASE3)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trelstar CI brief — competitive landscape report
- Trelstar updates RSS · CI watch RSS
- Verity portfolio CI